Tafenoquine and Primaquine in Colostrum and Breast Milk

NCT ID: NCT04984759

Last Updated: 2024-04-04

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-07-01
• Study Completion Date: 2025-06-30

Brief Summary

Each year almost a million infants are born small for gestational age due to malaria infection in pregnancy. These infants are at risk for stillbirth or neonatal death, and being born too small predisposes the survivors to increased metabolic diseases later in life. Plasmodium vivax (PV) is the second most common malaria species globally. Its relapsing nature results in multiple episodes of PV in a single pregnancy, compounding growth restriction and stillbirth risk. Women with PV in one pregnancy may harbor dormant parasites (hypnozoites) in their liver the cause illness and poor fetal growth in a subsequent pregnancy.

Only radical cure with 8-aminoquinolines (8AQ)- primaquine (PMQ) or tafenoquine (TQ) - can eliminate hypnozoites, but these drugs are contraindicated in pregnancy. The postpartum period presents a key window of opportunity for giving radical cure to women of childbearing age with PV. Pharmacokinetic data is needed to support safe use of these drugs postpartum and World Health Organization has identified pharmacokinetic studies of 8AQ in lactation as a research priority.

Primaquine is excreted minimally in mature breast milk, at <1% of the weight-adjusted relative infant dose (RID). As the main adverse event associated with both 8AQ - hemolysis glucose-6-phosphate dehydrogenase (G6PD) deficient individuals - is dose-dependent and negligible at low doses, this finding strongly supports its safe use in later lactation. This study is needed to determine if primaquine can also be given safely in the early postpartum period. There is no published data on tafenoquine excretion in breastmilk, and this study would quantify safety throughout early and late lactation.

Drug safety studies in lactation are essential to ensure medications are not denied and unnecessary interruption of breastfeeding is avoided. Demonstration of safety of radical cure for breastfeeding women in the postpartum period would allow women with PV in pregnancy and lactation to receive 8AQ after delivery, preventing illnesses in the postpartum period and subsequent pregnancies. Improved uptake of radical cure through elimination of unnecessary contraindications supports malaria elimination and community health.

The main purpose of this study is to characterize the transfer of tafenoquine and primaquine in breast milk of mothers receiving radical cure doses of 8AQ throughout the different phases of lactation - colostrum, transitional milk, and mature milk - in order to determine the degree of infant exposure.

Detailed Description

The study will take place at clinics of the Shoklo Malaria Research Unit (SMRU), Mahidol-Oxford Tropical Medicine Research Unit in Tak Province, Thailand. The clinics serve a population of migrant workers resident along the Thailand-Myanmar border. Non-pregnant breastfeeding women that access care at SMRU (postnatal care, outpatient, vaccine and routine baby care departments) will be invited to participate with their breastfed children.

All lactating women and their children will be G6PD phenotypically normal. Participants will be enrolled as follows; Arm 1: Primaquine mother-neonate pairs Arm 2: Tafenoquine mother-child pairs Arm 3: Tafenoquine mother-neonate pairs

Pharmacokinetic sampling plan:

• PMQ pharmacokinetic sampling (Mother/Neonate pairs - Arm 1):

• Mothers: Dense pharmacokinetic venous blood and breast milk sampling will be performed during day 1 and 14; one sample of blood and breast milk will collected at a single timepoint on days 3, 5 and 8.
• Neonate: One capillary blood sample will be collected on the same days as maternal sampling.
• TQ pharmacokinetic sampling (Mother/child pairs - Arms 2, and 3):

• Mothers: Dense pharmacokinetic venous blood and breast milk sampling will be performed during the first day after dosing, followed by one sample of blood and breast milk at a single time point on days 2, 3, 8, 15, 29, 43 and 75 (allowing a description of approximately 95% of the total drug exposure).
• Child: One capillary blood sample will be collected on the same days as maternal sampling.

Mothers and children will be closely monitored for safety throughout the 75 day follow up period including regular assessments of adverse events, Hb, Hct and MetHb levels. Pharmacokinetic drug measurements of primaquine, carboxyprimaquine and tafenoquine will be performed at the Department of Clinical Pharmacology, Mahidol-Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand. Drug concentrations will be quantified by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Interim data review will be done by an external drug safety monitoring board (DSMB) before recruitment of Arm 3. The board will review safety data and any available PK data. If PK data is not yet available and there are safety concerns, recruitment in Arm 3 may be suspended until PK data from Arms 1 and 2 are available.

Study participants with any adverse events will be followed until the event has stabilized or resolved (unless the participant refuses such follow up care). Free care will be offered through SMRU clinics. For severe harm caused by study procedures following this protocol, Oxford University insurance will support additional health care beyond SMRU's capacity.

This study is funded by Thrasher Research Fund.

Conditions

Healthy Lactating Women

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Primaquine in colostrum and transitional milk (mother-neonate pairs)

12 women who are breast feeding neonates ≤5 days old will be recruited into the primaquine arm. They will receive primaquine 0.5 mg/kg daily for 14 days directly observed in the clinic.

Group Type: EXPERIMENTAL

Primaquine

Intervention Type: DRUG

Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).

Tafenoquine in mature milk (mother-child pairs)

24 women who are breast feeding infants or young children \> 14 days will be recruited into Arm 2. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic. Investigators will begin with recruiting 2-4 women breastfeeding young children ≥12 months old.

Group Type: EXPERIMENTAL

Tafenoquine

Intervention Type: DRUG

Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.

Tafenoquine in colostrum and transitional milk (mother-neonate pairs)

12 women who are breast feeding neonates ≤ 5 days old will be recruited into Arm 3. They will receive a single 300 mg dose of tafenoquine directly observed in the clinic.

Group Type: EXPERIMENTAL

Tafenoquine

Intervention Type: DRUG

Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.

Interventions

Primaquine

Primaquine GPO® (Government Pharmaceutical Organization (GPO), Thailand) 0.5 mg/kg will be given once daily with food for 14 days. This is the dose recommended for radical cure of P. vivax in tropical areas with high rates of relapse, such as the study design setting. Doses will be directly supervised (DOT).

Intervention Type: DRUG

Tafenoquine

Tafenoquine (Kodatef, Biocelect Pty Ltd.) 300 mg will be given as a directly observed single dose with food. This is the standard dose recommended globally for radical cure of P. vivax.

Intervention Type: DRUG

Other Intervention Names

Primaquine GPO®; Kodatef

Eligibility Criteria

Inclusion Criteria

• Mother

• Lactating women >= 16 years old who are breast feeding one child who fits the time window for the respective study arm
• Planning to breastfeed for the duration of the study
• Willingness and ability to comply with the study protocol for the duration of the study
• Willingness to delay pregnancy until the end of the period of drug exposure (14 days for PMQ and 90 days for TQ)
• Current pregnancy excluded by urine pregnancy test and ultrasound OR immediate postpartum status (≤2 months)
• Can understand information about the study and provide consent
• Children

• Healthy children falling into the time window for the respective study arm
• ≤ 5 days for Arms 1 & 3
• > 14 days for Arm 2

Exclusion Criteria

• Mothers

• Known hypersensitivity to PMQ or TQ, defined as history of erythroderma/other severe cutaneous reaction, angioedema or anaphylaxis
• Known Glucose-6-phosphate-dehydrogenase (G6PD) deficiency in mother defined as G6PD activity <70% of normal male population median by spectrophotometry
• Presence of any condition which in the judgement of the investigator would place the participant at undue risk or interfere with the results of the study
• Alkaline phosphatase (ALT) > 2x the upper limit of normal (ULN)
• Pregnancy
• Screening hematocrit (Hct) <33%
• Known history of severe jaundice in a previous child
• Known history of psychiatric illness or abnormal depression screening score
• Blood transfusion within the 3 months before screening
• Children

• Known hypersensitivity to primaquine or tafenoquine, defined as history of erythroderma/other severe cutaneous reaction, angioedema or anaphylaxis
• Known Glucose-6-phosphate-dehydrogenase (G6PD) deficiency in child defined as G6PD activity <70% of normal male population median by spectrophotometry in children
• Presence of any condition which in the judgement of the investigator would place the participant at undue risk or interfere with the results of the study
• Screening Hct <33%
• Estimated gestational age at birth < 38 weeks
• Blood transfusion within the 3 months before screening
• Evidence of birth asphyxia (5 min Apgar score <7)
• Moderate or severe jaundice as defined as total serum bilirubin above treatment line on day 1 (before maternal dose)

• Minimum Eligible Age: 16 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Mahidol Oxford Tropical Medicine Research Unit

OTHER

Sponsor Role: collaborator

University of Oxford

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Rose McGready, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Shoklo Malaria Research Unit (SMRU), PO Box 46, 68/30 Ban Toong Road, Mae Sot, Tak 63110

Locations

Shoklo Malaria Research Unit (SMRU)

Mae Sot, Changwat Tak, Thailand

Countries

Thailand

Other Identifiers

MAL21004

Identifier Type: -

Identifier Source: org_study_id